ORIGINAL RESEARCH article

Front. Immunol., 13 April 2022

Sec. Cancer Immunity and Immunotherapy

Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.859331

RETRACTED: CCDC88A Post-Transcriptionally Regulates VEGF via miR-101 and Subsequently Regulates Hepatocellular Carcinoma

Retracted

A retraction of this article was approved in:

  1. Retraction: CCDC88A post-transcriptionally regulates VEGF via miR-101 and subsequently regulates hepatocellular carcinoma

    1. Read retraction
Qiongying HuQiongying Hu1Yuchen LiYuchen Li1Hongqing ChenHongqing Chen1Hongyan LiaoHongyan Liao2Yong HeYong He2Qin Zheng*Qin Zheng2*
  • 1Department of Laboratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
  • 2Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Hu Q, Li Y, Chen H, Liao H, He Y and Zheng Q (2022) CCDC88A Post-Transcriptionally Regulates VEGF via miR-101 and Subsequently Regulates Hepatocellular Carcinoma. Front. Immunol. 13:859331. doi: 10.3389/fimmu.2022.859331

Received: 04 February 2022; Accepted: 14 March 2022;
Published: 13 April 2022; Retracted: 25 September 2024.

Edited by:

Saravanan Sekaran, Saveetha Dental College and Hospitals, India

Reviewed by:

Ananth Kumar Kammala, University of Texas Medical Branch at Galveston, United States
Ezhilarasan Devaraj, Saveetha University, India

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.